chrisvoncsefalvay/vaers-outcomes huggingface dataset:
tingling on her lips; Top of tongue itching; This is a spontaneous report from a contactable consumer (patient).  A 25-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 vaccine, solution for injection, Batch/Lot Number: EW0186), via an unspecified route of administration, administered in Arm Left on 20Aug2021 at 09:30 Am (at the age of 25-years-old) as dose 1, single for covid-19 immunisation. Medical history included obesity, Chronic asthma from an unknown date and unknown if ongoing. The concomitant medications were none. On 20Aug2021 10:15, 45 minutes after vaccination, the patient experienced tingling on her lips, top of tongue itching. Patient stated 45 minutes post vaccination she felt itchiness on the top of her tongue and tingling on her lips. It was reported that she took Benadryl and that she is on the way to her physician. She took Benadryl and went to sleep for an hour and 30 minutes. When she woke up her lips were sill tinging, but not swollen. She can still feel her lips tingling after the COVID vaccine, but it got better because of Benadryl. Therapeutic measures taken for the events. The outcome of the event tingling on her lips was recovering while for Top of tongue itching was Recovered on Aug2021.  Follow-up attempts are completed. No further information is expected.
Exposed to the virus; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of Exposed to Covid19 in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced Exposed to Covid19. At the time of the report, EXPOSURE TO SARS-COV-2 Exposed to Covid19 outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was unknown.       No concomitant product use was provided by the reporter.   No treatment medications were reported.
Fever, chills,severe body aches, fatigue. Headache for 7 days
Area is red, inflamed itchy. 17 x 11 cm - local reaction, red and induration. Cephalexin 250/mg/5mL 2 teaspoon three times a day for 10 days. Triamcinolone acetonide 0.1% apply three times a day for seven days.
Felt flu-like symptoms: full-body aching, chills, fatigue, shortness of breath and headache.  Developed significant rash/bruising over left deltoid/upper arm.
Mother reports patient's left arm was red half way down arm and up to shoulder with swelling present. Reports no change in child's behavior. Redness resolved by 01/24/10, mother reports has scratches on arm from itching it during time of reaction. Mother took child to hospital 01/16/10, but was not seen by doctor. No medications other than TYLENOL and MOTRIN were given.
2nd anthrax shot - rt upper arm hard bump, itched, reddened area.
This is a spontaneous report from a contactable female consumer, the grandmother of the patient. A 1-year-old male patient possibly received a dose of PREVNAR 13 on an unspecified date. Relevant medical history and concomitant medication were not reported. The patient developed pneumonia on an unspecified date. The outcome of the event was unknown. The reporter suspected that the event could be related to PREVNAR 13 but did not really know if the child had been vaccinated with PREVNAR 13 or not. Follow-up (21FEB2012) Follow-up attempts completed. No further information expected.
Not any severe symptoms until about 3AM on 10/06/23.   Patient woke up with dizziness, lightheadedness, elevated blood pressure of 161/74.  This blood pressure was higher than the patients normal.  Spouse was taking him to urgent care to be seen.
This is a spontaneous report from a contactable nurse. A 19-years-old female patient of an unspecified ethnicity received TRUMENBA, intramuscular in the arm on an unspecified date at 0.5 ml, single. The patient medical history and concomitant medications were not reported. The patient experienced nausea, dizziness, chills on 21Jun2016 with outcome of not recovered. The symptoms were worsening and they started worsening after she worked out, after exercising. The patient was treated with TYLENOL dose in the night. Follow-up (18AUG20160): Follow-up attempts are completed. No further information is expected.
Pt received vaccines (PENTACEL, Hep B, PREVNAR, & ROTATEQ) on 4/1 - evening of 4/3 pt developed hives without respiratory compromise. No fever no seizures.
A few hours after the vaccines, she broke out in a facial rash and fever. She was lethargic and had no appetite. She fell asleep sitting up at 7:00 pm. The next morning her legs were both covered in rashes as well, and eczema flared up on her thighs and underarms. She had fever and rashes for a week. I didn't take her back to the Doctor for these concerns because I was always told her rashes and fevers and eczema flare ups are "normal" side effects of vaccines. Within a few weeks she developed anxiety that caused panic attacks. Eventually we took her to a counselor. The counselor decided Felicity was already receiving the best care she could get (through parenting and school), and wasn't concerned for her development or safety.
A report has been received from a literature source via regulatory authority, vaccine adverse event reporting system (VAERS) concerning a female patient. The patient's medical history, concomitant diseases and concomitant medications were not reported. On an unknown date, the patient received FLUMIST (intranasal) while she was pregnant. The patient was diagnosed with threatened abortion. The outcome of the events were unknown. Also the outcome of pregnancy was unknown. The report was considered to be non-serious. Based on the information in this report, and awaiting the reporter's assessment, the company physician considered the event of threatened abortion to be not related to FLUMIST. The company causality was implied to be no for drug exposure during pregnancy.
paralysis; lost 100 percent use of my left bicep; Parsonage Turner Syndrome; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NEURALGIC AMYOTROPHY (non-serious) with onset 04May2021, outcome "unknown", described as "Parsonage Turner Syndrome"; PARALYSIS (medically significant), outcome "unknown"; MUSCULAR WEAKNESS (non-serious), outcome "unknown", described as "lost 100 percent use of my left bicep".  Clinical course: It was reported that, their COVID 19 vaccine gave the patient Parsonage Turner Syndrome on 04May2021. Stated that, patient had all the medical records to back up claims. Enquired, what did Pfizer intend to do about the paralysis caused by their drug. Patient had lost 100 percent use of left bicep. What was their official statement about this?  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Soreness has now progressed up into her right shoulder; Soreness at the injection site; Redness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Soreness at the injection site), VACCINATION SITE ERYTHEMA (Redness at the injection site) and ARTHRALGIA (Soreness has now progressed up into her right shoulder) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and CLL. Concomitant products included HYDROCHLOROTHIAZIDE, AMLODIPINE and BISOPROLOL for Blood pressure high.    On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jan-2021, the patient experienced VACCINATION SITE PAIN (Soreness at the injection site) and VACCINATION SITE ERYTHEMA (Redness at the injection site). On 03-Feb-2021, the patient experienced ARTHRALGIA (Soreness has now progressed up into her right shoulder). On 03-Feb-2021, VACCINATION SITE ERYTHEMA (Redness at the injection site) had resolved. At the time of the report, VACCINATION SITE PAIN (Soreness at the injection site) and ARTHRALGIA (Soreness has now progressed up into her right shoulder) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
Pain at shot location; swelling; chills; headache; body aches; fatigue; This is a spontaneous report from a contactable other healthcare professional (hcp). A 55-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) first dose on 18Dec2020 13:00 (lot 121820, expiry date not reported), then second dose on 08Jan2021 15:30 (lot EK9231, expiry date not reported); both intramuscular in the left arm at a single dose for COVID-19 immunization. There were no medical history and concomitant medications. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. The patient was not pregnant at the time of the vaccination. The patient had no other vaccine in four weeks and no other medications in two weeks. The vaccines were administered in a hospital. On 09Jan2021 06:30, the patient experienced pain at shot location, swelling, chills, headache, body aches and fatigue. Post vaccination, patient had COVID test nasal swab (PCR) on 05Jan2021 and the results was negative. The events were reported as not serious (did not result in death, not life-threatening, did not cause/prolonged hospitalization, not disabling/incapacitating and not a congenital anomaly/birth defect). The patient did not receive any treatments in response to the events reported. The patient was recovering from the events pain at shot location, swelling, chills, headache, body aches and fatigue.
A report was received from a health care professional on 11/10/03, concerning a 35 year old female vaccinee who developed erythema at the injection site on 10/10/03 after receiving Fluvirin vaccine on 10/09/03. On 10/10/03 the vaccinee developed erythema at the injection site after receiving Fluvirin on 10/9/03. The event resolved 2 days later. There was insufficient information to determine the reporter's causality assessment. No follow up pending.
This spontaneous case was reported by a consumer and describes the occurrence of DYSPEPSIA (Horrible heartburn) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPEPSIA (Horrible heartburn). At the time of the report, DYSPEPSIA (Horrible heartburn) outcome was unknown. Relevant concomitant medications were not provided. Treatment information was not provided.
COVID-19 Vaccine breakthrough case that was hospitalized due to severity of symptoms.   On 9/15/21, the case was reported to be at home, isolating in their trailer. Symptoms began 9/9/21, and include runny nose/sinus congestion, fatigue, cough. Case was admitted to the local hospital on 9/17/21. Health Dept was contacted by family member on 9/20/21: 'Case's wife is now positive. She told me today that he is now in the ICU at the hospital admitted on 9/17/21. He is receiving the max amount of oxygen. She mentioned he was in very bad shape.'
vaccines were administered to patients prior to having them evaluated/does not have complete temperature excursion; Information has been received from an office manager concerning a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, drug reactions/drug allergies and concomitant medications were not reported.  It was reported that on 18-JAN-2021, the patient was vaccinated with a 0.5 mL dose of varicella virus vaccine live (oka/merck) (VARIVAX) (Lot # T003707 and expiration date 30-JAN-2022), subcutaneous for prophylaxis.  Other suspect vaccine given on the same day included a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (dose, frequency, route, Lot # and expiration date not provided).      It was reported that the vaccines were administered to patients prior to having them evaluated and the reporter still did not have cumulative and complete temperature excursion information to have them evaluated.  This is one of several cases from the same source (US-009507513-2102USA004608).; Sender's Comments:  US-009507513-2102USA004608:
79 year old female, presents to ED via wheelchair. Patient is accompanied by her husband. Patient states that she has been having abdominal pain since last night and it is getting worse. Patient admits to vomiting x1 this morning. Patient has had two bowel movements today. Patient has recently started back up on chemo for ovarian cancer.  transferred to higher care.   reason for visit: Abdominal Pain  Diagnoses   Small bowel obstruction  Encounter for nasogastric (NG) tube placement  Epigastric pain  Abdominal pain, generalized  Nausea  Elevated troponin level  Dehydration
Subsequent to Plaintiff's ZOSTAVAX inoculation, Plaintiff was treated (...) for shingles and other zoster-related conditions.; Subsequent to Plaintiff's ZOSTAVAX inoculation, Plaintiff was treated (...) for shingles and other zoster-related conditions.; Information has been received from a lawyer regarding a case in litigation concerning a patient (pt) of unknown age and gender. The pt's medical history, concurrent conditions and concomitant medications were not provided. On or about 01-OCT-2012, the pt was inoculated with a dose of zoster vaccine live (ZOSTAVAX) (exact dose, strength, dose number, lot #, expiration date, site and route of administration were not provided) as prescribed and/or administered by a pharmacist at a pharmacy for the long-term prevention of shingles and zoster-related conditions. On an unknown date, subsequent to the pt's inoculation with zoster vaccine live (ZOSTAVAX), the pt was treated by a physician for shingles and other zoster-related conditions. As a direct and proximate result of the pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, the pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs included care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the events was considered to be not recovered. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).
Patient received MMRV live vaccine while taking sirolimus (immunosuppressant), which is contraindicated. Sirolimus stopped for 1-2 weeks after vaccination administered on 5/3/23 and patient being monitored for reaction. No reaction reported as of 5/7/23.
Pt recvd Engerix-B on 7MAY90, 5JUN90, 29OCT90 subsequently was found neg Anti-HBS p/3 doses @ 1mo, 2mo, & 6mo intervals;
Information has been received on 12-SEP-2017 regarding a case in litigation from a lawyer and a female consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medication were not reported. On or about 30-MAY-2012, the patient was inoculated with ZOSTAVAX (lot number and expiration not reported) subcutaneous by a physician, as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 10-SEP-2014, the patient was treated by a physician for a vesicular outbreak, which was diagnosed as shingles. The patient has been prescribed sulfamethoxazole, trimethoprim (BACTRIM) for management of her painful and persistent symptoms. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, pain and suffering, and other damages. Additional information has been requested.
Local symptoms-pain-discomfort . General symptoms-chills, headaches muscle pains, fatigue. Narrative:
Client reports that she had muscle aches, fever of 101 degrees, very sore and red throat, pain in teeth on left side, lethargy, backache and reports feeling like "she has the flu". Also reports redness, swelling, and warmth at the site of the Tdap vaccine in left deltoid area.
Information has been rec'd from a hlth professional concerning a female pt  who was vaccinated with a 1st dose of pneumococcal vaccine 23 polyvalent (lot#640577/0995L). Subsequently the pt experienced severe cellulitis from her shoulder to her elbow. Unspecified medical attention was sought. Follow-up information indicated that within 1 day of vaccination, the pt called the office complaining of swelling, redness and heat at the injection site extending down her arm. She was seen in the office and it was reported that she experienced swelling., redness and heat from the injection site to past her elbow. The pt was treated with antibiotics and methylprednisolone (Medrol) . It was reported that the pt did not require hospitalization ad she subsequently recovered. The nurse reported that 2 other pt's had similar experiences following exposure pneumococcal vaccine 23 polyvalent (WAES#021USA02826 and 0201USAO0520). The reporter expressed a concern regarding the lot number. The records of testing prior to release of this lot have been checked by GMP Compliance and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. Upon internal review the patient's cellulitis was considered to be an other important medical event. Additional information has been requested.
The patient received monovalent 2nd booster dose on Wednesday, 8/31/2022.
Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Additional Details: hives on trunk and arms 4 days after vaccine, no other changes in daily life, very itchy and classic hives presentation
Received 2nd vaccine on 2/20/21. Started having some tightness in her throat and tingling on her tongue the next day. Two days later started having dizziness, and itchy rash and SOB, chills, and nonproductive cough. Went to ER on 2/24/21
Weakness in lower extremities; lack of sensation; hyper sensation; Unusual gait; Dizziness; nausea; vertigo; This is a spontaneous report from a contactable consumer (patient reporting for himself). A 32-year-old male patient received the second dose of BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in the left arm on 09Apr2021 15:30 (batch/lot number was not reported) at the age of 32 years old, as DOSE 2, SINGLE for COVID-19 immunization. The vaccine was administered at a vaccine facility. Patient's medical history included ankylosing spondylitis from an unknown date. The patient was not diagnosed with COVID-19 infection prior to vaccination. Concomitant medication included hydrocortisone (HUMERA) taken for an unspecified indication, start and stop date were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in the left arm on 19Mar2021 07:00 AM (batch/lot number was not reported) at the age of 31 years old, as DOSE 1, SINGLE for COVID-19 immunization. On 18Apr2021 08:00 AM, the patient experienced weakness in lower extremities, lack of sensation, hyper sensation, unusual gait, dizziness, nausea, and vertigo. The events resulted in doctor or other healthcare professional office/clinic visit and were reported as serious resulting in disability or permanent damage. Therapeutic measures were taken as a result of the events which included physical therapy. The patient has not recovered from the events. Since the vaccination, the patient has been tested for COVID-19; the Nasal Swab test on 30Jul2021 was negative and the Antibody test (Blood test) on 30Jul2021 was positive.   The batch/lot number for BNT162B2 was not provided and will be requested during follow-up.
nerve pain and couldn't move her arm; nerve pain and couldn't move her arm; 1st dose Pfizer COVID-19 Vaccine: Date Received: Apr2021/2nd dose Pfizer COVID-19 Vaccine: Date Received: 15Jul2021; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old female patient received BNT162b2 (BNT162B2), on 15Jul2021 as dose 2, single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Hyperthyroid" (unspecified if ongoing); "Thyroid" (unspecified if ongoing). Concomitant medication(s) included: TAPAZOLE taken for thyroid disorder. Vaccination history included: Bnt162b2 (1st dose Pfizer COVID-19 Vaccine:, Date Received: Apr2021, Lot number: unknown, Route of Administration: Intramuscular), administration date: Apr2021, when the patient was 53 years old, for Covid-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 15Jul2021, outcome "unknown", described as "1st dose Pfizer COVID-19 Vaccine: Date Received: Apr2021/2nd dose Pfizer COVID-19 Vaccine: Date Received: 15Jul2021"; NEURALGIA (non-serious), outcome "unknown", JOINT RANGE OF MOTION DECREASED (non-serious), outcome "recovered" and all described as "nerve pain and couldn't move her arm". Additional Information: When she had the 2nd part of the 1st vaccine, the vaccine was put in her shoulder capsule and had nerve pain and couldn't move her arm. She did make sure she has padding on her shoulder and not feeling like that. She couldn't tell she couldn't move her left arm till the next morning.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
2nd Shot given 21 days after the first shot. Next day seemed like normal side effects. Day 2 those effects went away low grade fever, aches, but had a knot axillary lymph node, and my arm hurt worse then the swelling spread to my chest and neck. No trouble breathing.  I went to the ER because the swelling was getting worse and they did a CT scan and gave me IV fluids. The CT scan revealed swollen lymph nodes.
hostpital for covid pneumonia three days later cough fatigue throwing up diahrea headache fever